Karyopharm Therapeutics Inc.
KPTI
$5.40
$0.459.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -21.25% | -9.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -21.25% | -9.36% | |||
| Cost of Revenue | -390.11% | -6.03% | |||
| Gross Profit | 10,214.38% | -54.27% | |||
| SG&A Expenses | -1.60% | -11.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.98% | -8.24% | |||
| Operating Income | -19.02% | 6.53% | |||
| Income Before Tax | 3.60% | -234.31% | |||
| Income Tax Expenses | -489.29% | -58.21% | |||
| Earnings from Continuing Operations | 4.03% | -234.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.03% | -234.80% | |||
| EBIT | -19.02% | 6.53% | |||
| EBITDA | -19.08% | 6.53% | |||
| EPS Basic | 4.72% | -270.16% | |||
| Normalized Basic EPS | 4.24% | -48.88% | |||
| EPS Diluted | 5.19% | -31.25% | |||
| Normalized Diluted EPS | 4.24% | -89.81% | |||
| Average Basic Shares Outstanding | 0.70% | 3.29% | |||
| Average Diluted Shares Outstanding | 0.70% | -19.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||